ClinicalTrials.gg
CompletedNCT05347745Updated Mar 24, 2025

Therascreen® KRAS RGQ PCR Kit

An interventional study of therascreen® KRAS RGQ PCR Kit in Colo-rectal Cancer, sponsored by QIAGEN Gaithersburg, Inc. Completed at 1 site in United Kingdom. Open to participants aged 17 Years to 99 Years. Per ClinicalTrials.gov, last updated 2025-03-24.

Sponsored by QIAGEN Gaithersburg, Inc (part of QIAGEN) · Not applicable, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Registered 3 months after the study started (first participant enrolled Jan 2022, registered Apr 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
219
Allocation
Not applicable
Ages
17 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 107 studies in Colonic Neoplasms with a site in United Kingdom — 16 open to participants now, 25 under way, 6 of them phase 3. Colonic Neoplasms · United Kingdom.

Enrollment
36th of 80
219 · median 173
Started
2022
with 7 others
No phase
20 of 107
2 open now
Registered
91st of 107
by date

Among the 107 studies in Colonic Neoplasms with a site in United Kingdom, this one is the 36th largest by enrollment of the 80 interventional ones that give a count, is one of 8 that started in 2022, is one of 20 with no phase, and was the 91st registered.

Colonic Neoplasms

2,457 studies on the registry are indexed under Colonic Neoplasms; 456 are open to participants now.

Browse Colonic Neoplasms studies →

Open to participants now

16 of the 107 studies in Colonic Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

11 more — sign in →

All 16 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 326 Colonic Neoplasms studies recruiting now, 202 (62%) set no upper age limit and 72 (22%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.

This study: 17 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 107 studies in Colonic Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

An interventional, prospective IVD device study for the testing of DNA extracted from tumor tissue biopsy samples from patients with Colorectal Cancer (CRC) who have previously tested positive for the KRAS G12C mutation for potential inclusion into the Amgen Phase III clinical trial (Protocol No 20190172) to demonstrate clinical performance of the therascreen® KRAS RGQ PCR Kit

Read the detailed description

This is an interventional, prospective clinical performance study protocol for the testing of DNA extracted from tumor tissue biopsy samples obtained from patients with CRC using the KRAS kit.

(RES, CNB are acceptable however (Fine needle aspiration (FNA), brushings, cell pellets from pleural effusion, bone biopsy and lavage samples are not acceptable.

Up to 200 patient tissue samples (from approximately 100 clinical trial sites), obtained in the Clinical Study (Protocol No. 20190172), will be tested using the KRAS Kit. The testing will be performed at the l device clinical testing sites, Q2 Solutions Laboratories in the two geographical locations: USA and UK.

The clinical study protocol (Protocol No. 20190172) requires an estimated total of 153 evaluable patient tissue biopsy samples to be tested. Approximately 200 patient biopsy samples are expected to be supplied to the test sites to reach this target.

The KRAS G12C mutation status of patients enrolling on the clinical trial is expected to be known prior to patient screening hence the relatively low estimate of screen failures. If existing local data are used for patient selection, the archival tumor sample is requested to be sent to the Test Site for confirmation of KRAS G12C status prior to enrollment. For the US (Site 001) and EU (Site 002) Test Sites a FFPE tissue block (preferred) and a copy of the de-identified pathology report is requested by the Test Site or a minimum of 9 - 20 unstained slides (4-5 µm) should be submitted during screening for prospective central confirmation.

If no remaining tumor tissue is available from the biopsy used for determining KRAS G12C status then an alternative archival tumor sample may be submitted to the Test Site. If this is unavailable or if there is insufficient quality of tumor sample, a new biopsy will need to be provided for central KRAS G12C confirmation.

The primary objective of the Amgen Clinical Study is to evaluate the progression free survival assessed by MODIFIED RECIST 1.1 criteria of Sotorasib (AMG 510) at 2 different dose levels as a combination therapy with panitumumab, compared to patients treated with investigators choice comparator (trifluridine and tipiracil or regorafenib) in patients using the Clinical Study Assay, therascreen®KRAS Kit to assess the presence of the KRAS G12C mutation in CRC, a key eligibility criteria.

The clinical data from the study will be used to determine the drug-device efficacy to support future regulatory submissions for the device-drug combination.

03

Conditions studied

  • Colo-rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
17 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with documented colorectal cancer (CRC).
  2. Patients identified for inclusion in the Amgen Clinical Study (Protocol No. 20190172) who have signed and dated a valid form.
  3. Patients must provide an or a fresh tumor biopsy at baseline if an appropriate archival sample is unavailable.
  4. Local KRAS data must be available for patient selection.
  5. An archival tumor sample or fresh tumor biopsy is required for central confirmation of KRAS G12C status prior to enrollment.
  6. Patient samples must meet the following criteria:

    1. A formalin-fixed paraffin-embedded (FFPE) tissue block (preferred) along with a de-identified pathology report.
    2. If an FFPE tissue block is unavailable, a minimum of 9-20 unstained slides (4-5 μm) must be submitted during screening for prospective central confirmation.
    3. If remaining tumor tissue from the KRAS status biopsy is unavailable, an alternative archival tumor sample may be submitted.
    4. If an alternative archival sample is unavailable or of insufficient quality, a new biopsy must be provided for central KRAS G12C confirmation.

    Submitted slides must be prepared using positively charged glass slides and cut within the past five years.

  7. Patient samples must have been collected using one of the following methods:

    1. Core needle biopsy (CNB)
    2. Surgical resection (RES)
    3. Lavage samples

Exclusion criteria

Exclusion Criteria:

  1. Patients who do not meet all eligibility criteria for the Amgen Clinical Study (Protocol No. 20190172).
  2. Patients with samples collected using one of the following methods:

    1. Fine needle aspiration (FNA)
    2. Brushings
    3. Cell pellets from pleural effusion
    4. Bone
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
219 participants (actual)

Study arms

  • Other
    Clinical Performance Study Protocol for therascreen® KRAS RGQ PCR Kit

    The therascreen® KRAS RGQ PCR Kit is a real-time qualitative PCR assay used on the Rotor-Gene Q MDx (US) instrument for the detection of seven somatic mutations in the human KRAS oncogene, using DNA extracted from formalin-fixed, paraffin-embedded (FFPE), colorectal cancer (CRC) tissue

    Diagnostic Test: therascreen® KRAS RGQ PCR Kit

Interventions

  • Diagnostic testtherascreen® KRAS RGQ PCR Kit

    Utilize a Clinical Trial Assay, the KRAS Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190172) in order to identify patients with CRC with KRAS G12C mutation positive tumors This will allow the clinical data from the study to be used to determine the drug-device efficacy to support future regulatory submissions for the device-drug combination.

06

What researchers measure

Primary outcomes

  1. therascreen® KRAS RGQ PCR Kit

    Device study is to utilize a Clinical Trial Assay, the KRAS Kit, as a screening test in Phase 3 of Clinical Study (Protocol No. 20190172) in order to identify patients with CRC with KRAS G12C mutation positive tumors

    Time frame: 5 business days

  2. The number of patients identified for enrollment into Amgen's Phase III clinical trial based on a KRAS G12C mutation detected test result.

    The primary objective of this device clinical performance study was to screen patients and confirm eligibility for enrollment into Amgen Phase III trail based on the detection of a KRAS G12C biomarker. If patents met all other eligibility criteria and were found to be KRAS G12C positive, they may enroll in the clinical trial. The primary outcome measure is the proportion pf patients tested with the QIAGEN therascreen KRAS RGQ PCR Kit that were KRAS G12C positive.

    Time frame: 12 months

07

Study locations

1 site
  • QIAGEN Gaithersburg, Inc
    Manchester, M130BH, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2022 to primary completion in Mar 2023, 14 months.

Of 404 interventional studies with no phase under Colonic Neoplasms, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 51. This study's 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 20, 2022
First posted
Apr 26, 2022
StartActual
Jan 7, 2022
Primary completionActual
Mar 30, 2023
CompletionActual
Apr 30, 2023
Last update
Mar 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05347745
Collaborators
Amgen
Responsible party
Sponsor
First posted
Apr 26, 2022
Start date
Jan 7, 2022
Primary completion
Mar 30, 2023
Completion
Apr 30, 2023
Last update
Mar 24, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion